Immediate Impact

1 by Nobel laureates 6 from Science/Nature 67 standout
Sub-graph 1 of 20

Citing Papers

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
2022 Standout
Psoriasis
2021 Standout
4 intermediate papers

Works of Richard Shames being referenced

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
2015
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
2006

Author Peers

Author Last Decade Papers Cites
Richard Shames 338 358 75 172 19 881
Reuben Falkoff 203 572 51 66 16 1.2k
Ellen Sher 619 324 91 56 15 1.0k
Denise Daley 326 135 165 55 37 935
Matteo Borro 258 174 112 74 22 747
Karin Söderberg 149 107 205 77 33 1.1k
Danielle Baum 139 390 49 280 14 764
Gertrude M. Möller 348 223 235 52 15 868
Stefan Ivanov 582 278 41 58 21 994
G. F. Ryan 736 243 74 63 11 1.0k
Michiel W. van der Linden 115 378 108 44 33 992

All Works

Loading papers...

Rankless by CCL
2026